MINUTES OF VMD MANAGEMENT BOARD MEETING HELD ON 4 SEPTEMBER 2018

<table>
<thead>
<tr>
<th>Members</th>
<th>Others Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julia Drown - Chair</td>
<td>Pete Borriello - CEO VMD</td>
</tr>
<tr>
<td>David Corner</td>
<td>Paul Green – VMD</td>
</tr>
<tr>
<td></td>
<td>Mike Griffiths – VMD</td>
</tr>
<tr>
<td>Observers</td>
<td>Linda Simmons - VMD</td>
</tr>
<tr>
<td></td>
<td>Chris Abbott – VMD: Note taker</td>
</tr>
</tbody>
</table>

VMD MANAGEMENT BOARD ONLY ITEMS:

1. Apologies for absence and announcements
   1.1 Apologies were received from Abigail Seager.

2. Declarations of interest in the matters to be discussed
   2.1 None.

3. Minutes of the last meeting
   3.1 The minutes of the last meeting were agreed with the addition that the terms of reference agreed at the last meeting were amended to delete reference to the Management Board reviewing Delegated Financial Authorities. It was decided to check if the revised terms of reference need to be approved by Defra.

ACTIONS

4. Matters Arising
   4.1 None.

5. EU Exit Opportunities
   5.1 VMD Directors explained that although there is lot of uncertainty about the outcome of Exit, it is likely to lead to opportunities for the VMD to be more flexible and innovative. There are plans to become a world leader in the assessment and authorisation of novel products, and there will be opportunities to reduce the regulatory burden, provided this doesn’t affect ability to trade, and to focus on endemic and preventative treatments. There are also plans to investigate the authorisation of veterinary devices, which are currently outside the scope of the regulations.

5.2 Exit will create opportunities to develop our global strategy, forming regulatory co-operation with countries outside the EU, such as Australia and New Zealand, and continuing to strengthen links with Sub-Saharan African countries. The VMD aims to become a world leader in the fight against antibiotic resistance, which has recently been supported by the WHO’s approval for the collection of antibiotic data from Thailand. There will also be an initiative to develop joint work with other countries, subcontracting work as non-EU experts and exploring joint labelling, as well as offering training to other regulatory authorities and industry. The VMD has a number of assets which could be valuable to other countries, including the IT systems it has developed for carrying out its work and its expertise in biological products.

5.3 Members were impressed by the action already undertaken and the plans that have been put in place.

#1444195
6. **Review of Risk Policy**  
6.1 Members were content to continue their approach to evaluating risk by assessing it on a case by case basis.

7. **CEO’s Report**  

7.1 Members reviewed the CEO’s Report and noted updates on the following:

- The VMD has secured funding over 4 years through the Fleming Fund in support of its bid to be an AMR conference centre.
- The outcome of an international workshop held in Bruges was a consensus that the VMD should lead on establishing a global coalition of Veterinary Medicines Regulation Agencies, to be launched in March 2019.
- Renewal of the VMD’s Investors In People Silver Award had been successfully achieved.
- Following the suspension of products containing diethanolamine on the grounds of consumer safety, authorisation holders have been given time to repackage their products.

8. **Delivery against the Business Plan 2018/19**  
8.1 Members noted the business plan. The amber risk areas were discussed and it was agreed that parts of the business plan (2B 1.1, 2C1.2 and 2) would be updated for 18/19.

9. **Finance Reports**  
9.1 Members noted the latest report showing income for authorisations being lower that the lower forecast that had been set for this year. However, other income was expected to make up for this reduction. It was noted that further financial forecasting is currently being undertaken.

The Board discussed the difficulty with managing the research budget effectively. The CEO said that he would be taking these issues to the next meeting of the research committee.

10. **Management Board Work Plan**  
10.1 It was noted that there would be an update from the Residues team at the December meeting. The CVO would be asked if they could attend the March 19 meeting.

11. **Any Other Business**  
11.1 It was noted that an exercise to recruit a new Non-Executive Director was ongoing.

12. **Future meetings**  
12.1 The next meeting will be held on 18 December 2018.

Veterinary Medicines Directorate  
September 2018